Regenerative Medicineto reverse bone-loss
Bone targeting platform to treat rare bone-diseases
Mesentech developed a novel drug conjugate that can deliver medicines selectively to the bone. Our first drug candidate, C3, reverses bone loss.
Stepping Stones to The Futureof Bone Regeneration
Healthy bone architecture(100x)
Mesentech's bone anabolic drug conjugates will be incrementally developed as a treatment for renal osteodystrophy, osteogenesis imperfecta, and Duchenne associated osteoporosis.
A topical formulation is being developed as a bone graft material to speed osseointegration in orthopedic and oral-maxillofacial indications while avoiding the cost and morbidity associated with harvesting self-donor material for autografts.
Learn more about our science
Science
If you are interested in partnering, we’d love to hear from you.
info@mesentech.com
Executive Team
VancouverCompany headquarters
Robert YoungFounder & President
• 30+ years leading discovery at Merck resulting in $80B+ in revenue from development of Singulair®. Vioxx®, Arcoxia®, Previcox®, Tredaptive® and odanacatib • Recipient of Heros of Chemistry award and the Order of Canada award • Two time recipient of Prix Galien (UK and Canada)
Jon PolakCEO
• Head of Business Development at Novateur Ventures • Founder and former CEO of Datapoint Diagnostics • Co-founder of C7bio • Deep international experience in clinical development, financing, regulatory strategy, pharmaceutical partnerships, recruiting angel investors, asset sale and patenting • Speaks 5 languages having lived and worked in China, Israel, Brazil, US & Canada.
Michael UnderhillCo-founder & Chief Science Officer
• Leading foundational research on mechanisms underlying bone formation • Co-founder of Corigen and Nexigen • Professor of Microbiology & Immunology at UBC
Peter SavasExecutive Chairman
• Serial CEO with 8 positive exists for shareholders • Current CEO of Likeminds • Formerly CEO of Alseres Pharma • Chairman and CEO of Aderis Pharmaceuticals, developer of the Neupro® trans-dermal patch marketed worldwide to treat Parkinson’s disease • Chairman and CEO of Unisyn, a cGMP contract manufacturer of biologics for clinical trials • leadership positions with Bristol Meyers, Waters, Millipore, Genex and Zymark.
Meet the whole team
